SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending following positive FDA feedback, which confirms a clear regulatory path for its lead drug in hidradenitis suppurativa without requiring additional clinical trials. This significant de-risking event has revitalized community discussions, with many investors anticipating substantial revaluation and renewed buyout speculation, especially given past acquisition interest and the drug's potential across a broader range of inflammatory conditions.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is experiencing significant market attention following reports that its Airobotics subsidiary is a prime contractor for Israel's multi-layered border security drone system, alongside broader excitement over increasing global defense budgets. The community is actively discussing the company's strong positioning in autonomous defense and AI-powered drone technology, anticipating substantial growth and potential for future contracts ahead of its upcoming Investor Day.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending lower amid significant selling pressure, sparking widespread community debate and frustration over its unexpected decline, with many questioning the lack of clear immediate news driving the drop. Investors are actively discussing concerns about Apple's perceived lag in the burgeoning AI sector and recent news of Google surpassing its market capitalization. Despite the downturn, some traders view the current levels as a compelling buying opportunity, while others point to market manipulation as a factor in the sustained weakness.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. is trending after providing an update and outlook that emphasized strong growth for its AI-powered Nociscan back pain platform and a solid, debt-free financial status. Community discussion centers on the company's exceptionally low public float, fueling expectations for sharp price movements, though some investors remain wary given its history of share structure adjustments. This puts the company at the forefront of conversations around innovative diagnostics in the medtech space.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending after releasing interim Real-World Evidence data demonstrating DefenCath's significant efficacy in reducing bloodstream infections and hospitalizations. While the community recognizes this as strong validation for DefenCath's potential as a standard of care and its market exclusivity, discussions also reflect ongoing frustration over the stock's price action and perceived market manipulation, alongside the broader impact of the Melinta acquisition.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending due to intense speculation surrounding a potential short squeeze, fueled by its low float and high cost to borrow. The community is actively discussing extreme price targets and a possible parabolic run, drawing parallels to its own past volatility, while also noting its blockchain-based tracing technology for material verification.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending due to significant developments, including its involvement in the White House's eVTOL Integration Pilot Program to launch air taxi trials in major U.S. cities and its collaboration with NVIDIA on next-generation AI for aviation. Investors are actively debating Archer's strategic pivot towards defense applications, expanded international presence, and the crucial upcoming milestones for eVTOL airworthiness certification and piloted flights, positioning 2026 as a pivotal year for the company's long-term potential in urban air mobility.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience (RGC) is trending due to intense speculation around an extreme short squeeze, fueled by an ultra-low float, zero shortable shares, and a skyrocketing borrow rate. The community is actively comparing its potential for parabolic price action to past volatile "Hong Kong tickers" and meme stock events. Despite acknowledged concerns about its fundamentals, traders are eyeing a significant upward move as shorts face immense pressure.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is a focal point for investors after delivering a strong earnings report that exceeded revenue and profitability expectations, highlighting its rapid expansion into high-performance computing. The community is actively discussing the company's robust pipeline, including advanced negotiations for significant new data center capacity, which could substantially increase its contracted revenue and potentially pressure short positions. This momentum positions the company as a key infrastructure provider in the booming AI sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Bluebird Bio (BLUE) Reports Q1 Loss, Lags Revenue Estimates

Bluebird Bio, Inc. (BLUE) said on Wednesday that global investment firms Carlyle (CG) and SK Capital Partners have agreed to purchase all its outstanding shares and take the company private for $5 per share upfront.Under the terms of the <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.bluebirdbio.com/news-releases/news-release-details/carlyle-sk-capital-partners-and-bluebird-bio-amend-merger">amended</a> agreement, Bluebird stockholders can elect to receive either $3 per share in cash plus a contingent value right (CVR) of $6.84 per share in cash payable upon achievement of a net sales milestone or $5 per share in cash.The upfront payment of $5 represents a 51% premium to Bluebird’s closing price of $3.31 on Tuesday.Shares of the company traded over 50% higher on Wednesday morning.Gene therapy maker Bluebird first entered a definitive agreement with Carlyle and SK Capital in February. As per the original agreement, stockholders had only one option of receiving $3.00 per share in cash plus a CVR of $6.84 per share.Bluebird said the amended agreement allows an alternative for stockholders who would prefer greater upfront cash consideration instead of the potential upside of the CVR.The Bluebird board of directors recommended that shareholders tender their shares in support of the transaction by 11:59 p.m., New York City time, on May 29, 2025, following which the tender offer would expire.The company said that unless a majority of stockholders tender their shares, Bluebird is at significant risk of defaulting on its loan agreements with Hercules Capital, and it is extremely unlikely that stockholders would receive any consideration for their shares in a bankruptcy or liquidation.On Stocktwits, retail sentiment around Bluebird rose within the ‘bullish’ territory while message volume jumped from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:633/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_14_at_10_22_02_AM_png_1451c7b7eb.webp" alt="BLUE's Sentiment Meter and Message Volume as of 10:20 a.m. ET on May 14, 2025 | Source: Stocktwits" width="633" height="60"><figcaption>BLUE's Sentiment Meter and Message Volume as of 10:20 a.m. ET on May 14, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/BLUE">BLUE stock</a> is down by about 43% this year and about 77% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dynatrace-technology-q4-2025-earnings/chiqru4RbNS">Dynatrace Stock Rises On Upbeat Q4 Earnings, Retail Turns Extremely Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Bluebird bio logo is seen on a smartphone and a pc screen in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Bluebird Bio Stock Soars On Higher Upfront Payment Under Amended Merger Deal: Retail Gets More Bullish 

The upfront payment of $5 represents a 51% premium to Bluebird’s closing price of $3.31 on Tuesday.

Equity

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases. It also offers ZYNTEGLO or beti-cel and SKYSONA or eli-cel gene therapies. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Somerville, MA.

Bluebird bio Inc

SpaceX

Discord

OpenAI

Other - Comment Below

A few major private companies are being discussed as potential IPO candidates in 2026 — including SpaceX, Discord, Databricks, OpenAI, Anthropic, and Deel. IPO timelines can shift, but if one of these listings happens this year, which are you most excited to watch?

Which Potential 2026 IPO Are You Most Excited For?

BLUE
Bluebird bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest BLUE News

BLUEBluebird bio Inc